Thank you to our speakers, sponsors, and delegates who joined us in 2025 for the summit! If you are interested in the 2026 event, please get in touch at [email protected]

Achieving Clinically Validated, Selective Degraders & Proximity- Based Therapeutics by Rapidly Identifying Novel Ligase-Substrate Pairs, Enhancing Oral Bioavailability & Limiting Off-Target Toxicity

2025 EVENT GUIDE

Welcome to the 5th TPD & Induced Proximity Summit Europe

Accelerating PROTAC’s, Glues & Novel Non-Degrading TACs to Patients Faster

Induced proximity medicines are revolutionising therapeutic strategies, offering groundbreaking solutions for disease treatment.

In 2024 alone, PhoreMost secured $50 million in Series B financing for its degrader programs, while Merck KGaA partnered with C4 Therapeutics in a $756 million deal focused on protein degraders.

However, challenges remain in making PROTACs orally bioavailable, effectively discovering molecular glues, and developing non-degrading proximity therapeutics.

Join the The 5^th TPD Summit Europe to network with over 100 experts and learn about the latest advancements in degraders (PROTACs, lysosomal, surface, and ECM), molecular glues, and non-degrading proximity therapeutics. Accelerate your research and bring innovative therapies to patients faster.